We are live on ! Find out more
SC

Stempoint Capital Portfolio holdings

AUM $522M
1-Year Est. Return 281.95%
This Fund
S&P 500
This Quarter Est. Return
+5.16%
1 Year Est. Return
+281.95%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$401M
AUM Growth
+$66.6M
Cap. Flow
+$201M
Cap. Flow %
50.06%
Top 10 Hldgs %
50.8%
Holding
80
New
26
Increased
21
Reduced
6
Closed
26

Top Buys

Rank Stock Value
1
SNDX icon
Syndax Pharmaceuticals
SNDX
+$19.5M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$15.5M
3
NUVL
Nuvalent
NUVL
+$13.6M
4
IMVT icon
Immunovant
IMVT
+$12.7M
5
ALKS icon
Alkermes
ALKS
+$10.6M

Top Sells

Rank Stock Value
1
FOLD
Amicus Therapeutics
FOLD
+$15.8M
2
ARQT icon
Arcutis Biotherapeutics
ARQT
+$14M
3
APLT
Applied Therapeutics
APLT
+$13.2M
4
AUTL
Autolus Therapeutics
AUTL
+$9.5M
5
DAWN
Day One Biopharmaceuticals
DAWN
+$7.06M

Sector Composition

Rank Sector Weight
1 Healthcare 99.15%
2 Financials 0.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TERN
76
DELISTED
Terns Pharmaceuticals
TERN
– –
-449,321
Closed -$3.75M
URGN icon
77
UroGen Pharma
URGN
$1.96B
– –
-241,984
Closed -$3.07M
VIGL
78
DELISTED
Vigil Neuroscience
VIGL
– –
-743,719
Closed -$2.53M
ZURA icon
79
Zura Bio
ZURA
$518M
– –
-1,044,168
Closed -$4.24M
MBX
80
MBX Biosciences
MBX
$2.99B
– –
-50,000
Closed -$1.3M
1 2 3
4

Similar funds

JE
JMAC Enterprises Newtown, Pennsylvania $522M AUM 15.34% 1-Year Est. Return
GS
GWN Securities Palm Beach Gardens, Florida $523M AUM 20.1% 1-Year Est. Return
LT
Legacy Trust Grand Rapids, Michigan $522M AUM 23.56% 1-Year Est. Return
WFA
WestHill Financial Advisors San Rafael, California $523M AUM 15.95% 1-Year Est. Return
TCM
TruNorth Capital Management Kalamazoo, Michigan $522M AUM 14.26% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
ETS
ESL Trust Services Rochester, New York $524M AUM 17.18% 1-Year Est. Return
CM
Conifer Management New York $524M AUM 14.11% 1-Year Est. Return

Stempoint Capital's Q4 2024 Portfolio in Review

As of Q4 2024, Stempoint Capital held 80 positions worth $401M, up 20% from $334M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Stempoint Capital deployed $201M of net new capital in Q4 2024, opening 26 new positions and adding to 21 existing holdings. Its largest new stake was Xenon Pharmaceuticals: 375,845 shares worth $14.7M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Arcutis Biotherapeutics, an estimated $14M trimmed.

  • Stempoint Capital's largest Q4 2024 buy was Xenon Pharmaceuticals: 375,845 shares worth $14.7M.
  • Stempoint Capital added most to Syndax Pharmaceuticals in Q4 2024, an estimated $19.5M increase.
  • Stempoint Capital's biggest Q4 2024 reduction was Arcutis Biotherapeutics, cutting an estimated $14M.
  • Stempoint Capital fully exited Amicus Therapeutics in Q4 2024, selling an estimated $15.8M.
  • Stempoint Capital's ten largest holdings make up 51% of its $401M portfolio in Q4 2024.
  • Stempoint Capital opened 26 new positions and closed 26 in Q4 2024.
  • Stempoint Capital's portfolio value rose 20% quarter-over-quarter to $401M.

Based on Stempoint Capital's 13F filing for Q4 2024, filed 14 Feb 2025.